Kairos Pharma (NYSEAMERICAN:KAPA) Releases Quarterly Earnings Results

Kairos Pharma (NYSEAMERICAN:KAPA) released its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, FiscalAI reports.

Kairos Pharma Trading Up 1.7%

KAPA traded up $0.01 during trading on Tuesday, reaching $0.56. 30,945 shares of the company were exchanged, compared to its average volume of 155,788. Kairos Pharma has a 52 week low of $0.40 and a 52 week high of $2.11. The stock has a market cap of $11.64 million, a P/E ratio of -1.80 and a beta of 2.28. The firm has a 50 day moving average of $0.63 and a 200 day moving average of $0.84.

Institutional Trading of Kairos Pharma

Several hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Kairos Pharma during the 2nd quarter valued at about $44,000. Two Sigma Investments LP bought a new position in Kairos Pharma in the 3rd quarter worth approximately $54,000. Finally, FNY Investment Advisers LLC acquired a new stake in Kairos Pharma in the 3rd quarter valued at approximately $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.